Malignant breast cancers are difficult to cure, especially highly metastatic triple-negative breast cancers (TNBC) lacking estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) molecules as therapeutic targets1,2. Here, ERBB2 is linked to triple-negative breast carcinoma.